For patients with 3rd-line+ multiple myeloma (MM) after a proteasome inhibitor (PI) and an immunomodulatory agent,

DARZALEX® Monotherapy Efficacy

Share

Sirius_Mobile_Trial_Page_Badge

DARZALEX® (daratumumab)

Overall response rate (ORR)1†

29%

sCR=stringent complete response; VGPR=very good partial response; PR=partial response.
  • DARZALEX® achieved sCR + VGPR in 12% of patients1

*Efficacy results were based on ORR as determined by an Independent Review Committee assessment using International Myeloma Working Group criteria.1,2

In the trial, sCR was defined as complete response (CR) plus a normal serum free light chain (FLC) ratio and the absence of clonal plasma cells in the bone marrow by immunohistochemistry or immunofluorescence or 2- to 4-color flow cytometry.3

 

DARZALEX® provided a 7.4-month median duration of response (range: 1.2 to 13.1+ months)

Median time to response was 1 month
(range: 0.9 to 5.6 months)1

 

DARZALEX® is indicated:

  • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy
  • as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent